Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Paul Turnbull

- PMLiVE

Gilead builds case for Descovy PrEP after FDA approval

Reported statistically significant improvements in kidney function

- PMLiVE

J&J pledges $500m investment into HIV and tuberculosis R&D

Aims to help eliminate both diseases by 2030

- PMLiVE

Understanding the patient journey

What we can learn from customer service

- PMLiVE

J&J bags FDA breakthrough designation for prostate cancer drug

Could challenge rival PARP inhibitor Lynparza

- PMLiVE

Aspen to pay millions to NHS following drug pricing investigation

CMA found company colluded to create a monopoly in UK market

- PMLiVE

Gilead claims FDA okay for Descovy as second PrEP option

Can now push new indication before generics dent franchise

- PMLiVE

Arbutus hit hard as new hep B drug fails on safety

Shares have fallen sharply since company reported results

#LucidLife is just about to get better with the move to Middlesex House

With only a few weeks to go Jan Steele, Lucid co-founder and COO discusses how the move to Middlesex House supports its commitment to making Lucid a great place to...

Lucid Group Communications Limited

- PMLiVE

Sarepta rival NS Pharma files Duchenne drug with FDA

Another blow for Sarepta following FDA rejection earlier this year

- PMLiVE

UK bans some drug exports to preserve NHS stocks

Insists the move is not related to Brexit

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

- PMLiVE

The business case for patient engagement

Using digital to bridge the engagement gap between patients and pharma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links